Segall Bryant & Hamill LLC Acquires 93,922 Shares of Novo Nordisk A/S (NYSE:NVO)

Segall Bryant & Hamill LLC lifted its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 41.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 318,540 shares of the company's stock after acquiring an additional 93,922 shares during the period. Segall Bryant & Hamill LLC's holdings in Novo Nordisk A/S were worth $37,929,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. 1620 Investment Advisors Inc. acquired a new stake in shares of Novo Nordisk A/S during the second quarter worth about $25,000. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S in the second quarter worth $25,000. Gilliland Jeter Wealth Management LLC grew its position in Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company's stock valued at $26,000 after purchasing an additional 120 shares in the last quarter. Halpern Financial Inc. increased its stake in Novo Nordisk A/S by 113.0% in the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company's stock valued at $30,000 after buying an additional 113 shares during the last quarter. Finally, Abound Wealth Management lifted its position in Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company's stock worth $31,000 after buying an additional 157 shares in the last quarter. Institutional investors own 11.54% of the company's stock.

Analyst Ratings Changes

A number of analysts recently issued reports on the company. StockNews.com raised Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, November 1st. Cantor Fitzgerald reissued an "overweight" rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Finally, BMO Capital Markets lowered their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $144.50.

Novo Nordisk A/S Stock Performance

Shares of NYSE NVO traded up $2.40 during mid-day trading on Wednesday, reaching $105.03. 3,793,931 shares of the company were exchanged, compared to its average volume of 4,479,583. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15. The stock has a market capitalization of $471.33 billion, a P/E ratio of 33.22, a P/E/G ratio of 1.31 and a beta of 0.42. The company's 50-day simple moving average is $117.40 and its 200-day simple moving average is $129.27. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.